IP Library › Granted Patent US 11,260,026
Granted Patent B2
US 11,260,026 · App. 16/713,052 · Granted Mar 1, 2022

Ready to use diclofenac stick packs

Inventors: Alberto Reiner (Como, IT); Giorgio Reiner (Como, IT)
Assignee: APR Applied Pharma Research SA
A61K9/08A61K9/0053A61K31/196A61K47/02A61K47/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,260,026
App. No.
16/713,052
Granted
Mar 1, 2022
Kind
B2
Abstract

Ready to use liquid formulations of diclofenac potassium are disclosed which are particularly well suited for packaging in stick-packs.

Claims (64)

1. A liquid diclofenac formulation in a ready to use stick pack comprising:

a) a therapeutically effective amount of diclofenac or a pharmaceutically acceptable salt thereof;

b) from about 0.05% to about 1.5% of an alkalizing agent imparting a pH of from about 7 to about 10 to the formulation; and

c) a sugar-based aqueous means for solubilizing and stabilizing said formulation.

2. The formulation of claim 1 comprising about 50 mg of diclofenac or a pharmaceutically acceptable salt thereof in from about 8 to about 25 or 50 g of said formulation.

3. The formulation of claim 2 , wherein said sugar-based aqueous means comprises a sugar selected from the group consisting of mono-, di-, tri-, and tetra- saccharides and sugar alcohols and combinations thereof.

4. The formulation of claim 2 , wherein:

a) said sugar-based aqueous means comprises a sugar selected from monosaccharides and sugar alcohols and combinations thereof;

b) said monosaccharides are selected from the group consisting of fructose; and

c) said sugar alcohols are selected from the group consisting of glycerol; erythritol;

xylitol; sorbitol; maltitol; and combinations thereof.

5. The formulation of claim 1 comprising:

a) from about 0.1% to about 1% diclofenac or a pharmaceutically acceptable salt thereof;

b) from about 0.05% to about 1.5% bicarbonate; and

c) from about 95% to about 99.85% of said sugar-based aqueous means.

6. The formulation of claim 1 wherein said sugar-based aqueous means comprises:

a) from about 0% to about 95% water; and

b) from about 5% to about 95% of a fruit sugar or monosaccharide or a combination thereof.

7. The formulation of claim 1 wherein said sugar-based aqueous means comprises:

a) from about 0% to about 95% water; and

b) from about 5% to about 95% of a fruit sugar or monosaccharide or a combination thereof comprising:

i) from about 10% to about 90% sorbitol; and

ii) from about 10% to about 90% of xylitol, maltitol, glycerol, fructose, erythritol or a combination thereof.

8. The formulation of claim 1 wherein said sugar-based aqueous means comprises:

a) from about 0% to about 40% water; and

b) from about 60% to about 80% of a fruit sugar or monosaccharide or a combination thereof comprising:

i) from about 10% to about 90% sorbitol; and

ii) from about 10% to about 90% of xylitol, maltitol, glycerol, fructose, erythritol or a combination thereof.

9. The formulation of claim 1 wherein said sugar-based aqueous means comprises:

a) from about 0% to about 60% water; and

b) from about 40% to about 90% of sorbitol, xylitol, maltitol, glycerol, fructose, erythritol or a combination thereof.

10. The formulation of claim 1 wherein said sugar-based aqueous means comprises:

a) from about 0% to about 75% water; and

b) from about 25% to about 75% of xylitol.

11. The formulation of claim 1 wherein said sugar-based aqueous means comprises:

a) from about 0% to about 75% water; and

b) from about 25% to about 75% of maltitol.

12. The formulation of claim 1 wherein said sugar-based aqueous means comprises:

a) from about 0% to about 75% water; and

b) from about 25% to about 75% of glycerol.

13. The formulation of claim 1 wherein said sugar-based aqueous means comprises:

a) from about 0% to about 75% water; and

b) from about 25% to about 75% of fructose.

14. The formulation of claim 1 wherein said sugar-based aqueous means comprises:

a) from about 0% to about 85% water; and

b) from about 15% to about 45% of erythritol.

15. The formulation of claim 1 having a density of from about 1.02 to about 1.5 g/ml.

16. The formulation of claim 1 wherein said diclofenac is present as diclofenac potassium and said bicarbonate is present as potassium bicarbonate.

17. The formulation of claim 1 wherein the formulation comprises from about 25% to about 90% non-crystallizing sorbitol.

18. A method of treating a condition selected from pain and migraine in a patient in need thereof comprising administering to said patient a therapeutically effective amount of the formulation of claim 1 .

19. The formulation of claim 3 , wherein said sugar-based aqueous means comprises;

a) a sugar selected from the group consisting of glucose, fructose, and galactose; or

b) a sugar alcohol selected from the group consisting of ethylene, propylene glycol, glycerol, erythritol, threitol, arabitol, xylitol, ribitol, mannitol, sorbitol, galactitol, fucitol, iditol, inositol, volemitol, isomalt, maltitol, lactitol, maltotriitol, maltotetraitol and polyglycitol.

20. A liquid diclofenac formulation in a ready to use stick pack comprising:

a) about 0.47% diclofenac potassium;

b) about 0.21% potassium hydrogen carbonate;

c) about 20% xylitol;

d) about 0.06% sucralose; and

e) water.

21. A method of treating pain or migraine in a patient in need thereof comprising administering to said patient a therapeutically effective amount of the formulation of claim 5 .

22. A method of treating pain or migraine in a patient in need thereof comprising administering to said patient a therapeutically effective amount of the formulation of claim 16 .

23. A method of treating pain or migraine in a patient in need thereof comprising administering to said patient a therapeutically effective amount of the formulation of claim 20 .

24. The formulation of claim 1 , wherein said alkalizing agent is selected from the group consisting of ammonia solution, ammonium carbonate, diethanolamine, monoethanolamine, potassium hydroxide, sodium borate, sodium carbonate, sodium bicarbonate, sodium hydroxide, triethanolamine, and trolamine.

25. The formulation of claim 1 , further comprising a flavoring agent, wherein said flavoring agent is selected from the group consisting of acacia syrup, acesulfame K, alitame, anise, apple, aspartame, banana, Bavarian cream, berry, black currant, butterscotch, calcium citrate, camphor, caramel, cherry, cherry cream, chocolate, cinnamon, bubble gum, citrus, citrus punch, citrus cream, cotton candy, cocoa, cola, cool cherry, cool citrus, cyclamate, cylamate, dextrose, eucalyptus, eugenol, fructose, fruit punch, ginger, glycyrrhetinate, glycyrrhiza (licorice) syrup, grape, grapefruit, honey, isomalt, lemon, lime, lemon cream, monoammonium glyrrhizinate, maltol, mannitol, maple, marshmallow, menthol, mint cream, mixed berry, neohesperidine DC, neotame, orange, pear, peach, peppermint, peppermint cream, raspberry, root beer, rum, saccharin, safrole, sorbitol, spearmint, spearmint cream, strawberry, strawberry cream, stevia, sucralose, sucrose, sodium saccharin, saccharin, aspartame, neotame, acesulfame potassium, mannitol, talin, xylitol, sucralose, sorbitol, swiss cream, tagatose, tangerine, thaumatin, tutti fruitti, vanilla, walnut, watermelon, wild cherry, wintergreen, xylitol, and mixtures thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2026
From: APR APPLIED PHARMA RESEARCH SA
To: ALKEMIRA SA
Reel/Frame 076110/0116 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 24, 2020
From: REINER, ALBERTO; REINER, GIORGIO
To: APR APPLIED PHARMA RESEARCH S.A.
Reel/Frame 054453/0172 →
Continuity (2)
Provisional Application 62779514 · Dec 14, 2018
Related Publication 20200197302A1 · Jun 25, 2020